“…According to the sum of the correlations of these 385 genes in gastrointestinal cancer, we screened the 30 genes with the strongest correlations, which are RARS1, BTF3, HSPA4, NSA2, HNRNPA1, EIF3M, CCT4, OLA1, UIMC1, G3BP1, NACA, RSL1D1, ETF1, MRPS27, RBM22, CCT8, GEMIN5, LARS1, PA2G4, CDK7, NIFK, RSL24D1, EIF3E, THG1L, INTS13, UBE2D2, RPS23, DIMT1, RIOK2, and TTC27 respectively. Previous studies have reported that overexpression of BTF3, CCT8, CDK7, ELF3M, G3BP1, HSPA4, OLA1, and RSL1D1 can contribute to the occurrence and development of CRC (Goh et al, 2011;Zhou et al, 2019; Frontiers in Pharmacology frontiersin.org Zhou et al, 2021b;Liao et al, 2021;Zhang et al, 2021;Liu et al, 2022a;Liu et al, 2022b;Li et al, 2022), overexpression of CCT4 and PA2G4 can contribute to the occurrence and development of LIHC (Li et al, 2021a;Sun et al, 2022), overexpression of DIMT1 and HNRNPA1 can contribute to the occurrence and development of STAD (Liu et al, 2017;Zhu et al, 2022), and overexpression of EIF3E and UIMC1 can contribute to the ESCA occurrence and development (Xu et al, 2018;Yang et al, 2018). Therefore, we believe that these genes have the potential to be called diagnostic and therapeutic targets of gastrointestinal cancer.…”